Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

· Issued by Phathom Pharmaceuticals, Inc.
Watch Phathom Pharmaceuticals explain itPhathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call · Replay · Jul 30
  • Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p